Kura Oncology Inc (NAS:KURA)
$ 8.86 -0.08 (-0.89%) Market Cap: 688.99 Mil Enterprise Value: 250.32 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 29/100

Kura Oncology Inc at Barclays Global Healthcare Conference Transcript

Mar 14, 2023 / 06:35PM GMT
Release Date Price: $11.72 (+4.46%)
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon and welcome to Barclays Global Healthcare Conference, do email me and my team if you have questions. And my name is Peter Lawson, and I'm one of the mid-cap biotech analysts at Barclays, cover and focus around oncology companies. Really delighted to have with us on stage Troy Wilson, CEO of Kura Oncology.

Questions & Answers

Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

And I guess with that I'd love to kind of touch upon definitely the menin inhibitor and kind of how we should expect kind of data to unfold, how much more data should we expect to see and I guess that's maybe earmarked for EHA.

Troy Edward Wilson
Kura Oncology, Inc. - Chairman, CEO & President

First of all Peter, thank you to you and Barclays for the invitation. In terms of the update, we've guided toward midyear, obviously, you have ASCO and EHA, it will be 1 of the 2 -- EHA would be a logical venue just so you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot